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Abstract
The association of Crohn’s disease (CD) and Sweet’s syndrome is rare and the presence of Sjo ¨gren’s syndrome in Crohn’s
disease is even rarer, with only three reports found in the literature. We describe two cases of Crohn’s disease associated with
Sweet’s syndrome, one of which is the ﬁrst case of CD and Sweet’s concomitantly associated with Sjo ¨gren’s syndrome. Both
cases responded rapidly to Inﬂiximab therapy with complete resolution of the skin lesions.
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Introduction
Robert Douglas Sweet ﬁrst described acute febrile
neutrophilic dermatosis, or Sweet’s syndrome, in
1964. The disorder is characterized by fever,
leukocytosis, acute eruption of painful erythematous
plaques and nodules on the face, neck, upper chest,
back and extremities. Other skin manifestations such
as vesicles, pustules, purpura, ulcers and hemorrhagic
lesions have been described. The overall female to
male ratio is 3.7:1 with the mean age of 52 years.
Su and Liu (1986) proposed two major and several
minor diagnostic criteria for Sweet’s syndrome
(Table I). Von den Driesch (1994) added elevated
erythrocyte sedimentation rate as a ﬁfth minor
criteria. For a deﬁnitive diagnosis, both major and
two minor criteria must be met. Clinical manifes-
tations are primarily dermatological, although acute
neutrophilic alveolitis, pleuropericardial effusion,
acute renal failure, aortitis, elevated transaminases
and aseptic meningitis have been described. The
histologic ﬁndings consist of diffuse, predominantly
neutrophilic dermal inﬁltrate with leukocytoclasis, a
marked vasodilatation and swelling of the vascular
endothelium. The pathogenesis of Sweet’s syndrome
is poorly understood and several mechanisms have
been implicated. There are conﬂicting reports of local
deposits of immunoglobulin and complement com-
ponents on the vessel wall, although leukocytoclastic
vasculitis and intravascular microthrombi are not
considered features of Sweet’s syndrome (von den
Driesch 1994).
Cohen et al. suggested that the production of
cytokines, such as G-CSF, interleukin (IL)-1, IL-6, or
IL-8, if deposited in the dermis, might be responsible
for the immunopathologic and clinical manifestations
(Cohen et al. 1992, Reuss-Borst et al. 1993). The fact
that Sweet’s syndrome can occur after G-CSF
treatment shows that IL-1, which is produced by
acute myelocytic leukemia (AML) cells and stimulates
the G-CSF gene, plays a role in the pathogenesis of
Sweet’ssyndrome(Parketal.1992,Grifﬁnetal.1993).
Many diseases with dermatologic manifestations
may resemble Sweet’s syndrome. Erythema nodosum
can at times be almost indistinguishable from Sweet’s
syndrome. Beside its association with Crohn’s disease,
Sweet’s syndrome has been recognized with many
other diseases, including infections, hemoproliferative
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Behcet’s syndrome, bowel-bypass syndrome and
rarely, vaccination or drug association (von den
Driesch 1994).
Only a few cases of Sweet’s syndrome associated
with Crohn’s disease have been reported in the
literature. The skin manifestations of Sweets syn-
drome may parallel the activity of Crohn’s disease in
some patients (Actis et al. 1995, Fett et al. 1995).
Prednisone or prednisolone at aninitialdoseof0.5–
1.5mg/kg of body weight per day, with gradual taper
over 2–4 weeks, represents the standard treatment for
Sweet’s syndrome (von den Driesch 1994). Kemmet
et al. (1990) demonstrated that 10% of their patients
had chronic relapsing disease for at least 3 years. In
recurrent disease, therapy with colchicine, potassium
iodide, dapsone, doxycycline, nonsteroidal anti-
inﬂammatory agents and cyclosporine have been
described with mixed results (Waltz et al. 1999).
Sjo ¨gren’s syndrome is an autoimmune disease of
unknown etiology affecting predominantly the sali-
vary, lacrimal and exocrine glands. Dry eyes and dry
mouth characterize primary Sjo ¨gren’s syndrome, also
called the Sicca syndrome. Secondary Sjo ¨gren’s
syndrome is associated with connective tissue diseases
especially rheumatoid arthritis (von den Driesch et al.
1989, Bartunkova et al. 1999). The disease affects
approximately 0.2% of adults, mainly older women
with a female to male ratio of 10:1 (Bartunkova et al.
1999). Vitali et al. (1993) proposed diagnostic criteria
for primary Sjo ¨gren’s syndrome (Table II). Recent
modiﬁcation of the diagnostic criteria requires the
presence of antibody to SS-A or characteristic ﬁndings
on minor salivary gland biopsy. The pathophysiology
of Sjo ¨gren’s syndrome is characterized by replacement
of initial B-lymphocytes and periductal inﬁltration
with T-lymphocytes, resulting in glandular and ductal
atrophy. However, the inﬁltrate does not extend
beyond the gland capsule and the normal lobular
pattern and salivary ductal epithelium tend to
persevere.
Sjo ¨gren’s syndrome may involve many organs, but
oral manifestations are the most common. The
patients have symptoms of sensitivity to acidic and
spicy foods, difﬁculty in eating dry foods and difﬁculty
in speaking and controlling dentures (von den Driesch
et al. 1989, Soto-Rojas et al. 1998). Oral examination
ﬁndings include dental caries, angular cheilitis,
ﬁssure-lobulated smooth tongue and oral candidiasis
(Soto-Rojas et al. 1998). Salivary gland enlargement
can occur in two-thirds of patients. Ocular involve-
ment is common and manifests with sensations of
grittiness, itching, dryness of the eyes, eye fatigue and
photosensitivity. Deﬁciency of mucin and lipid
production leading to decreased tear viscosity and
increased tear evaporation are the most important
Table I. Revised diagnostic criteria for Sweet’s syndrome.
Major Criteria
1. Abrupt onset of tender or painful erythematous plaques or
nodules occasionally with vesicles, pustules, or bullae.
2. Predominantly neutrophilic inﬁltration in the dermis without
leukocytoclastic vasculitis
Minor Criteria
1. Preceded by a nonspeciﬁc respiratory or gastrointestinal tract
infection or vaccination or associated with:
Inﬂammatory diseases such as chronic autoimmune disorders,
infections
Hemoproliferative disorders or solid malignant tumors
Pregnancy
2. Accompanied by periods of general malaise and fever (.388C)
3. Laboratory values during onset: ESR .20mm, C reactive protein
positive, segmented neutrophils .70% in peripheral blood
smear, leukocytosis .8000 (3 of 4 of these values are necessary)
4. Excellent response to treatment with systemic corticosteroids
or potassium iodide
Both major and two minor criteria are needed for diagnosis.
Taken from reference Su and Liu (1986).
Table II. Preliminary criteria for the classiﬁcation of Sjo ¨gren’s
syndrome.
1. Ocular symptoms
Deﬁnition: A positive response to at least one of the following
3 questions:
a. Have you had daily persistent, troublesome dry eyes for more
than 3 months?
b. Do you have a recurrent sensation of sand or gravel in the eyes?
c. Do you use tear substitutes more than 3 times a day?
2. Oral symptoms
Deﬁnition: A positive response to at least one of the following
3 questions:
a. Have you had a daily feeling of dry mouth for more than
3 months?
b. Have you had recurrent or persistently swollen salivary glands
as an adult?
c. Do you frequently drink liquids to aid in the swallowing dry
foods?
3. Ocular signs
Deﬁnition: objective evidence of ocular involvement, determined on
the basis of a positive result on at least one of the following 2 tests:
a. Schirmer-I test (# 5mm in 5 minutes)
b.Rosebengal score($ 4,according to thevanBijsterveld scoring
system)
4. Histopathologic features
Deﬁnition: Focus score $1mm on minor salivary gland biopsy
(focus deﬁned as an agglomeration of at least 50 mononuclear cells;
focus score deﬁned as the number of foci 4 mm
2 of glandular tissue)
5. Salivary gland involvement
Deﬁnition: objective evidence of salivary gland involvement,
determined on the basis of a positive result on at least one of the
following 3 tests:
a. Salivary scintigraphy
b. Parotid sialography
c. Un-stimulated salivary ﬂow (#1.5ml in 15 minutes)
6. Autoantibodies
Deﬁnition: presence of at least one of the following serum
autoantibodies:
a. Antibodies to Ro/SS-A or La/SS-B antigens
b. Antinuclear antibodies
c. Rheumatoid factor
Exclusion criteria: preexisting lymphoma, acquired
immunodeﬁciency syndrome, sarcoidosis, or graft-versus-host
disease.
Taken from reference Vitali et al. (1993).
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et al. 1998, Shimazaki et al. 1998). Other clinical
manifestations include, myositis, arthralgias, vaginal
dryness, intersititial lung diseases, cystitis and
peripheral neuropathy. Sjo ¨gren’s syndrome has been
associated with rheumatoid arthritis, lymphoma,
Waldenstro ¨m’s macroglobulinemia, thyroiditis,
primary biliary cirrhosis, pernicious anemia and
hepatitis C (Ramos-Casals et al. 1998, 1999).
Although the role of viral infections, environmental
conditions and predisposing genetic factors all have
been suggested, the pathogenesis of Sjo ¨gren’s syn-
drome remains unknown. Recruiting T-cells and
clonal expansion with release of cytokines like TNF-
alpha and IL-1 are believed to interfere with the neural
signals, causing inhibition of glandular secretions (Fox
et al. 1998, 1999).
Report of cases
Case 1
A 37-year-old Caucasian female with a four-year
history of CD presented with severe sore throat and
difﬁculty in swallowing. Her primary care physician
prescribed oral penicillin for the presumptive diagno-
sis of streptococcal pharyngitis. Three days later, she
developed mouth sores forming deep pits and she
became febrile to 408C. She also developed new
acneiform pustules on her abdomen, lateral thighs,
under her breasts, along her inner labia, face and
arms. She was then referred to a dermatologist for
evaluation.
Crohn’s disease therapy consisted of Inﬂiximab
infusions at 5mg/kg until three months prior to her
diagnosis of Sweet’s when her dose was increased to
10mg/kg every six weeks due to the severityof her CD.
She had been initially treated with CellCept and
6-Mercaptopurine (6-MP) for her Crohn’s disease but
developed pancreatitis. Current immunomodulator
therapy was methotrexate at 15mg a week by
injection.
Physical examination by the dermatologist revealed
1–1.5cm round, indurated, erythematous, annular
plaques on the right arm and mid abdomen.
In addition, scattered acneiform pustules were found
in the groin. The uvula was erythematous with a one
mm erosion on the right upper inner lip and clustered
erosions covered the buccal and gingival mucosa.
Laboratory tests were unremarkable except for a white
blood cell count of 10,000 with 85% neutrophils.Viral
and bacterial throat cultures and HSV immunoﬂuor-
escence testing from a skin lesion were negative.
A punch biopsy from a lesion on the right arm showed
histological features of Sweet’s syndrome.
Therapy was initiated with indomethacin and was
discontinued two days later due to severe nausea. The
patient’s skin lesions and symptoms did not improve.
She was therefore treated with a 10mg/kg infusion of
Inﬂiximab, which led to a complete resolution of her
skin lesions within 2–3 days. Subsequent therapy
consisted of maintenance Inﬂiximab therapy every
6 weeks and immunomodulation with methotrexate.
There has been no recurrence of the skin lesions or the
oral ulcers in the last 3 years.
Case 2
A 45-year-old Caucasian female was admitted for
severe low back pain after lifting a 75-pound sack. She
was treated with intravenous narcotic analgesia with
relief of pain. However, the patient developed a fever
of 398C with erythematous tender nodules on her
arms and legs requiring transfer to our medical center
for further management of presumed erythema
nodosum.
She had a 20-year history of CD, multiple small
bowel resections and a total colectomy. She was
diagnosed with erythema nodosum when similar
lesions developed with ﬂares of her CD in past. The
patient had been started on 6-MP by her gastroentero-
logist 2-weeks prior to admission for recurrent small
bowel CD. However, prior to transfer, the 6-MP was
discontinued and empiric therapy with intravenous
broad-spectrum antibiotics was initiated.
Physical examination revealed tachycardia at
120bpm, normal blood pressure and temperature of
39.58C. The abdomen was soft, nontender with active
bowel sounds, well-healed scars and an intact ostomy
bag. There were multiple 1–4cm poorly marginated,
erythematous nodules and few 1–3mm pustules on
her upper and lower extremities. She continued to be
febrile and became toxic with worsening of her skin
lesions. Laboratory tests revealed a white blood cell
count of 11,900/mm
3 with 94% neutrophils, hemato-
crit of 38.5% and platelets 230,000. Urine culture was
negative. Blood cultures were not drawn as the patient
was transferred on antibiotics. Liver function tests and
chemistry panels were normal. A chest X-ray,
abdominal and pelvic CT scans were unremarkable.
An ileoscopy revealed scattered aphthous ulcers.
She developed photophobia, a gritty feeling in the
eyelids, dry and sore mouth with difﬁculty in
swallowing. She also began to develop bilateral ﬁrm,
tender submandibular swelling extending to involve
the parotid glands. Her SS-A, SS-B antibodies,
rheumatoid factor and antinuclear antibodies were
all negative. Given her classical clinical ﬁndings, a
clinical diagnosis of Sjo ¨gren’s syndrome was made by
the consulting rheumatologist. She refused a parotid
gland biopsy but a punch biopsy of one of the skin
lesions revealed dermal neutrophilic inﬁltration,
subepidermal edema and no evidence of vasculitis
consistent with the diagnosis of Sweet’s syndrome.
She was started on prednisone 40mg daily and
experienced signiﬁcant improvement in her parotid
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then discharged on a tapering course of prednisone.
On follow up several weeks later, her parotid
enlargement had disappeared but her skin lesions
were not improving and she had started to have
ostomy site breakdown. Biologic therapy was then
started with Inﬂiximab 5mg/kg by intravenous
infusion. The skin lesions completely resolved within
one week.
Discussion
The association of Sweet’s syndrome and Sjo ¨gren’s
syndrome with Crohn’s disease has not been reported.
We found only six case reports of Sjo ¨gren’s syndrome
associated with Sweet’s syndrome in the literature,
and their association is probably immune-mediated
(Bianconcini et al. 1991, Vatan et al. 1997, Osawa
et al. 1997). Likewise, Crohn’s disease is also an
immune-mediated disease that begins with activation
of the intestinal immune system. The putative target
for this response is directed to the luminal commensal
bacteria. The increased mucosal production of TNF-
a found in Crohn’s disease is a pivotal ﬁnding, and
neutralization of TNF-a has been shown to be
efﬁcacious in the treatment of ﬁstulizing Crohn’s
disease (Present et al. 1999). Inﬂiximab is a chimeric
anti-TNF-a monoclonal antibody, which blocks the
binding of TNF-a to its transmembrane receptors
(Knight et al. 1993). Additionally, binding is
associated with apoptosis of the activated membrane
bound T-cells and results in a cellular immune
modulation. Literature reviews did not support an
association of 6-MP with either Sweet’s or Sjo ¨gren’s
syndrome. In a manner similar to Crohn’s disease
immune activation and resultant cytokine response,
Sweet syndrome has reported associations with
bacterial infections. We, therefore, believe the
development of these syndromes in our patients was
associated with the increased activity of the patients
Crohn’s disease and the resulting increased cytokine
response. Andersen and Tiede (1997) described a case
of a 43-year-old man, who developed joint pain, fever,
rash and serum sickness with acute lobular pannicu-
litis and vasculitis within 2-weeks of 6-MP therapy for
CD. Vasculitis is not a feature of Sweet’s syndrome
and its presence should direct a search for another
disease. The rapid response after receiving Inﬂiximab
therapy with complete resolution of symptoms and
complete resolution of the patient’s skin lesions was
quite impressive and unexpected. This observation
supports the role of TNF-a in the pathogenesis of
Sweet’s syndrome.
Severalstudieshavesupportedtheroleofcytokinesin
the development of Sweet’s syndrome. First, patients
with AML, the most common malignant neoplasm
associated with Sweet’s syndrome, have cells, which
produce IL-1 in vitro (Grifﬁn et al. 1993). Second,
Sweet’s syndrome has been described in patients after
receiving G-CSF therapy (Park et al. 1992). Finally,
high levels of G-CSF and IL-6 have been found in
patientsduring the acute phase ofSweet’s syndrome, as
opposed to the moderate rise in TNF-a level (Reuss-
Borst et al. 1993). Also, TNF-a has been found in the
salivary glands of patients with Sjo ¨gren’s syndrome.
These ﬁndings, together with the success of Inﬂiximab
in the treatment of Crohn’s disease imply the potential
beneﬁt of anti-TNF antibodies in the treatment of
refractory Sweet and Sjo ¨gren’s syndrome.
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